Ana sayfa
Piyasalar
Grafikler ve fikirler
Algo
Haberler
Store
Aracı kurumlar
İndir
Ekonomik Takvim
Alım-satım sinyalleri
Web Terminali
Arama yapmak için
/
tuşuna basın: @kullanıcı, $sembol, ...
Ara
Giriş yap
Hesap oluştur
Türkçe
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
LGVN
#538
Longeveron Inc. Common Stock
0.973
5
USD
+20.33%
Sektör:
Sağlık hizmetleri
Baz:
USD
Kar para birimi:
USD
Günlük aralık
Yıllık aralık
Günlük değişim
+20.33%
Aylık değişim
+70.40%
6 aylık değişim
+70.40%
Yıllık değişim
+70.40%
Önceki kapanış
0.809
0
Open
0.973
5
Bid
0.973
5
Ask
0.976
5
Low
0.973
5
High
0.973
5
Hacim
14
Piyasalar
ABD hisse senetleri
Sağlık hizmetleri
LGVN
Open full chart
Financials
Overview
Rapor
Statistics
Quarterly
Annual
Value
Q3, 24
Q4, 24
Q1, 25
Q2, 25
Q3, 25
TTM
Key stats
Total common shares outstanding
13.35 M
13.47 M
13.53 M
13.69 M
19.85 M
—
Valuation ratios
Enterprise value
63.55 M
58.28 M
55.49 M
29.16 M
38.81 M
181.74 M
Price to earnings ratio
-0.31
-0.66
-1.15
8.67
7.5
14.36
Price to sales ratio
5.53
6 806.57
14.92
7 769.21
6 353.48
20.94 K
Price to cash flow ratio
0.48
1 174.02
1.53
1 159.91
631.78
2 967.23
Price to book ratio
0.25
743.88
0.47
209.79
154.38
1 108.52
Enterprise value to EBITDA ratio
-3.77
-3.68
-3.3
-1.56
-1.81
-10.35
Profitability ratios
Return on assets %
0.15
0.16
0.24
0.3
0.46
1.16
Return on equity %
0.17
0.19
0.29
0.4
0.72
1.6
Return on invested capital %
268.26
254.32
321.8
347.02
484.79
1 407.92
Gross margin %
88.23
87.73
72.18
46.2
91.24
297.35
Operating margin %
601.42
710.28
1 359.84
1 707.91
5 335.77
9 113.8
EBITDA margin %
-562.61
-693.7
-1 307.35
-1 644.62
-5 189.78
-8 835.45
Net margin %
571.67
674.63
1 312.34
1 591.14
5 270.8
8 848.9
Liquidity ratios
Quick ratio
—
—
—
—
—
—
Current ratio
7.67
7.6
5.61
3.43
2.09
18.73
Inventory turnover
—
—
—
—
—
—
Asset turnover
0.03
0.02
0.02
0.02
0.01
0.06
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
—
—
Per share metrics
Operating cash flow per share
0
0
0
0
0
0
EBIT per share
-0
-0
-0
-0
-0
-0
EBITDA per share
-0
-0
-0
-0
-0
-0
Total debt per share
—
—
—
—
—
—
Cash per share
0
0
0
0
0
0
Net current asset value per share
0
0
0
0
0
0
Tangible book value per share
0
0
0
0
0
0
Working capital per share
0
0
0
0
0
0
Book value per share
0
0
0
0
0
0
Haberler
Longeveron 15 milyon dolarlık finansman kapattı
Longeveron closes $15 million financing, extends runway to 4Q26
Longeveron 15 milyon dolar finansman sağladı
Longeveron secures $15M financing, eyes $15M more on trial results
Longeveron faz 2b kök hücre deney sonuçlarını yayınladı
Longeveron publishes phase 2b stem cell trial results in journal
Longeveron, önemli deneme sonuçları öncesinde Stephen Willard’ı yeni CEO olarak atadı
Longeveron appoints Stephen Willard as new CEO ahead of pivotal trial results
Longeveron receives Japanese patent for stem cell potency assay methods
Longeveron prepares for pivotal HLHS therapy data with FDA meeting
Longeveron receives patent for stem cell therapy targeting female sexual dysfunction
Longeveron yöneticileri CVCT Forumu’nda hücre tedavisi denemeleri hakkında konuşacak